SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. __)*
China Pharma Holdings, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.001 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
16941T104
--------------------------------------------------------------------------------
(CUSIP Number)
Zhilin Li
President
2nd Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China
Telephone: 86-898-6681 1730
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 13, 2006
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[_].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 16941T104
________________________________________________________________________________
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Zhilin Li
________________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [X]
________________________________________________________________________________
3 SEC USE ONLY
________________________________________________________________________________
4 SOURCE OF FUNDS*
OO
________________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [_]
________________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
The People's Republic of China
________________________________________________________________________________
7 SOLE VOTING POWER
NUMBER OF
10,000,000 shares
SHARES _________________________________________________________________
8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
_________________________________________________________________
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
10,000,000 shares
PERSON _________________________________________________________________
10 SHARED DISPOSITIVE POWER
WITH
0
________________________________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,000,000 shares
________________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.8%
________________________________________________________________________________
14 TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1. Security and Issuer.
This statement relates to the common stock, par value $0.001 (the "Common
Stock") of China Pharma Holdings, Inc., a Delaware corporation (the "Company").
The Company's principal executive offices are located at 2nd Floor, No. 17,
Jinpan Road, Haikou, Hainan Province, China. 570216.
Item 2. Identity and Background.
(a) This statement is filed by Zhilin Li ("Ms. Li" or "Reporting Person").
(b) The business address of the Reporting Person is 2nd Floor, No. 17,
Jinpan Road, Haikou, Hainan Province, China. 570216;
(c) The Reporting Person is the director, president and CEO of the Issuer.
She is also the Chairman of the board of directors and president of
Hainan Helpson Medicine and Biotechnology Co., Ltd, the wholly owned
sub-subsidiary of the Issuer.
(d) Reporting Person has not, during the last five years, been convicted
in a criminal proceeding (excluding traffic violations or similar
misdemeanors);
(e) The Reporting Person has not, during the last five years, been a party
to a civil proceeding of a judicial or administrative body of
competent jurisdiction as a result of which was or is subject to a
judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such laws;
(f) The Reporting Person is a citizen of the People's Republic of China
Item 3. Source and Amount of Funds or Other Consideration.
Tsui Heung Mei ("Tsui") entered into a Stock Transfer Agreement (the
"Agreement") with the Reporting Person and the Issuer which was closed on
September 13, 2006. Pursuant to the Agreement, the Reporting Person acquired
from Tsui 10,000,000 shares of common stock of the Company held by Tsui.
Item 4. Purpose of Transaction.
The purpose of the acquisition of the shares of common stock reported herein by
the Reporting Person was for investment.
(a) The Reporting Person has no present plans or proposals relating to or
that would result in the acquisition by any person of additional
securities of the issuer, or the disposition of securities of the
issuer;
(b) The Reporting Person has no present plans or proposals relating to or
that would result in an extraordinary corporate transaction, such as a
merger, reorganization or liquidation, involving the issuer or any of
its subsidiaries;
(c) The Reporting Person has no present plans or proposals relating to or
that would result in a sale or transfer of a material amount of assets
of the issuer or any of its subsidiaries;
(d) On May 1, 2006, the Company filed a Form 8-K (the "Form 8-K") to
disclose that on May 1, 2006, the Board of Directors of the Company
increased the size of the Board from one to three and elected Zhilin
Li and Xinhua Wu as directors to serve until the next annual meeting
of shareholders and until their successors are elected and qualified.
Furthermore, on May 1, 2006, the Company filed a Certificate of
Amendment to its Articles of Incorporation ("the Amendment") in the
State of Delaware. The Amendment became effective immediately upon
filing. The Amendment effected the following changes: 1) Change of the
Company's name from TS Electronics, Inc. to China Pharma Holdings,
Inc.; 2) Increase in the number of the Company's authorized shares of
common stock from Thirty Million (30,000,000) shares to Sixty Million
(60,000,000) shares; and 3) Setting the number of directors
constituting the entire Board of Directors at between three and nine,
with the specific number to be fixed from time to time by a vote of
the majority of the entire Board of Directors.
The Form 8-K is incorporated herein by reference. Except as described
in the Form 8-K, the Reporting Person has no other present plans or
proposals relating to or that would result in any change in the
present Board of Directors or management of the Company, including any
plans or proposals to change the number or term of directors or to
fill any existing vacancies on the Board.
(e) The Company filed an amendment to the preliminary Schedule 14C on
March 15, 2006 (the "14C Amendment") relating to a consent of
shareholders dated March 15, 2006 that approved 1) Change of the
Company's name from TS Electronics, Inc. to China Pharma Holdings,
Inc.; 2) Increase in the number of the Company's authorized shares of
common stock from Thirty Million (30,000,000) shares to Sixty Million
(60,000,000) shares; and 3) Setting the number of directors
constituting the entire Board of Directors at between three and nine,
with the specific number to be fixed from time to time by a vote of
the majority of the entire Board of Directors. The Amendment is hereby
incorporated herein by reference. The Company filed a definitive
Schedule 14C on March 28, 2006 (the "Definitive Schedule 14C") with
the same contents as the 14C Amendment. The Definitive Schedule 14C is
hereby incorporated herein by reference. Except as described in the
14C Amendment and the Definitive Schedule 14C, the Reporting Person
has no present plans or proposals relating to or that would result in
a material change to the present capitalization or dividend policy of
the Company.
(f) Except as described in the Form 8-K, the Reporting Person has no
present plans or proposals relating to or that would result in any
other material change in the issuer's business or corporate structure
including but not limited to, if the issuer is a registered closed-end
investment company, any plans or proposals to make any changes in its
investment policy for which a vote is required by section 13 of the
Investment Company Act of 1940.
(g) Except as described in the Form 8-K, the 14C Amendment and the
Definitive Schedule 14C, the Reporting Person has no present plans or
proposals relating to or that would result in any changes in the
Company's charter, by-laws, or instruments corresponding thereto or
other actions which may impede the acquisition of control of the
Company by any person.
(h) The Reporting Person has no present plans or proposals relating to or
that would result in a class of securities of the Company being
delisted from a national securities exchange or to ceasing to be
authorized to be quoted in an inter-dealer quotation system of a
registered national securities association.
(i) The Reporting Person has no present plans or proposals relating to or
that would result in a class of equity securities of the issuer
becoming eligible for termination of registration pursuant to Section
12(g)(4) of the Securities Exchange Act.
(j) The Reporting Person has no present plans or proposals relating to or
that would result in any action similar to any of those enumerated
above.
Item 5. Interest in Securities of the Issuer.
(a) The Reporting Person is the beneficial owner of 10,000,000 shares of
common stock of the Company. The Company had 34,723,056 shares of
common stock outstanding as of September 14, 2006. Based on that
reported number of shares of common stock outstanding, The Reporting
Person has beneficial ownership of approximately 28.8% of the
Company's outstanding common stock.
(b) The Reporting Person has sole power to vote or direct to vote and sole
power to dispose or to direct the disposition of 10,000,000 shares of
common stock.
(c) Reference is made to Item 5(a) above for information regarding
transactions in Company's common stock effected by the Reporting
Person during the past 60 days.
(d) No other person has the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of such
securities.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
Other than as described above, to the best knowledge of the Reporting Person,
there are no contracts, arrangements, understandings or relationships (legal or
otherwise) between reporting person and any person with respect to any
securities of the issuer, including but not limited to transfer or voting of any
of the securities, finder's fees, joint ventures, loan or option arrangements
puts or calls, guarantees of profits, division of profits or loss, or the giving
or withholding of proxies, naming the , persons with whom such contracts,
arrangements understandin or relationship have been entered into.
Item 7. Material to be Filed as Exhibits.
None.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
September 21, 2006
By: /s/ Zhilin Li
----------------------------
Zhilin Li, President and CEO